GeneDx Holdings Corp. (WGS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

SA Transcripts158.92K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call GeneDx Holdings Corp. (WGS) Barclays 28th Annual Global Healthcare Conference March 11, 2026 3:00 PM EDT Company Participants Kevin Feeley - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Bank PLC, Research Division Presentation Luke SergottBarclays Bank PLC, Research Division All right. Good afternoon, everybody. I'm Luke Sergott. I cover life science tools and diagnostics here for Barclays. With me, I have Kevin Feeley, CFO of GeneDx. Thanks again for making it. It's always a pleasure to have you guys here. Question-and-Answer Session Luke SergottBarclays Bank PLC, Research Division You guys have been -- over the last couple of years, just been executing against our commercial targets, right, continuing to build out the platform. Why don't you just kind of walk us through the transition that you've had -- or not the transition, but the momentum that you've been building over the last couple of years, and where you are now and kind of how you're positioned there to jump off into '26 and beyond? Kevin FeeleyChief Financial Officer Yes, and thank you, everybody, for being here. I mean, GeneDx has operated for 25 years with a focus specifically in solving the world's hardest-to-diagnose cases around rare disease. For the past several years, really focused for the first time since 2021 with full commercial efforts behind our flagship whole exome and whole genome sequencing technology, a technology, we spent the better part of the last 2 decades refining. The core of the business had been expert clinical geneticists in the United States and about 2,000 of those really utilizing exome and genome as a last-in-line diagnosis for those hardest-to-crack cases. Most people over the past 2 decades hadn't heard of GeneDx unless you were a global expert in genetics and rare disease, and GeneDx is really